虫草肾茶胶囊对高糖培养下人肾小球系膜细胞影响的实验研究
|
摘要
目的：观察虫草肾茶胶囊对高糖培养条件下人肾小球系膜细胞(HMC)的影响，并探讨虫草肾茶胶囊对糖尿病肾病(DN)肾脏保护作用的机制。
方法：首先采用血清药理学的方法制备虫草肾茶胶囊及福辛普利药物血清，再进行药物血清干预HMC的研究。将常规培养的HMC分为正常对照组、高糖组、虫草肾茶高、中、低剂量组、福辛普利组，采用高糖模型(即高糖刺激体外培养的系膜细胞)进行研究。正常对照组予10％正常大鼠FCS改良型RPMI-1640培养液培养干预，高糖组予10％正常大鼠FCS改良型RPMI-1640高糖培养液培养干预，虫草肾茶高、中、低剂量组分别予10％虫草肾茶胶囊高、中、低剂量含药血清改良型RPMI-1640高糖培养液培养干预，福辛普利组予10％福辛普利含药血清改良型RPMI-1640高糖培养液培养干预。分别在相应干预因素处理后，于培养的24h、48h及72h用MTT法检测各组细胞增殖的情况；于相应干预因素作用48h及72h后，用ELISA法检测细胞培养液上清中转化生长因子-β1(TGF-β1)、纤维连接蛋白(FN)、Ⅳ型胶原(Col-Ⅳ)、层粘连蛋白(LN)的含量；用实时定量PCR方法检测人肾小球系膜细胞转化生长因子-β1mRNA(TGF-β1mRNA)、纤维蛋白溶解酶原激活物抑制剂-1mRNA(PAI-1mRNA)的表达。
结果：
(1)虫草肾茶胶囊高剂量药物血清对高糖(30mmol／L)刺激下24h、48h和72h的HMC的增殖均有抑制作用(p＜0.05，p＜0.01)，其作用优于福辛普利药物血清。虫草肾茶胶囊中、低剂量药物血清对高糖刺激下48h和72h的HMC的增殖有抑制作用(p＜0.05)。
(2)在48h和72h时段，虫草肾茶胶囊高、中剂量组TGF-β1的分泌明显低于高糖组(p＜0.05，p＜0.01)，而虫草肾茶胶囊低剂量药物血清及福辛普利药物血清对72h时段TGF-β1的分泌有抑制作用(p＜0.05)。在抑制TGF-β1的分泌方面，虫草肾茶胶囊优于福辛普利。
(3)虫草肾茶胶囊高、中、低剂量组及福辛普利组48h及72h HMCⅣ型胶原的合成均低于高糖组(p＜0.05，p＜0.01)。
(4)虫草肾茶胶囊高剂量组细胞培养上清中FN、LN在48h时段和72h时段的分泌均低于高糖组(p＜0.05，p＜0.01)，而虫草肾茶胶囊中、低剂量药物血清及福辛普利药物血清在72h时段可减少细胞培养上清中FN、LN的分泌(p＜0.05，p＜0.01)。
(5)虫草肾茶胶囊高、中剂量组及福辛普利组TGF-β1mRNA和PAI-1mRNA表达均低于高糖组，且以虫草肾茶胶囊高剂量组表达最低(p＜0.05)。
结论：虫草肾茶胶囊可以抑制高糖刺激下HMC的增殖，降低高糖刺激下TGF-β1及细胞外基质(ECM)主要成分FN、LN、Col-Ⅳ的合成和分泌，下调高糖刺激下HMC TGF-β1mRNA及PAI-1mRNA的表达，起到延缓DN进展的作用。
Objective:
To investigate the effects of Chongcaoshencha capsule on humanmesangial cells cultured in vitro under high glucose condition and explorethe nephroprotective mechanism of Chongcaoshencha capsule for DN.
Methods:
We first get the rats serum with different concentration of Chongcaoshenchacapsule and fosinopril, and then study the effects of the serum onHMCs. The cultured HMCs were divided into normal control group, highglucose group, High-dose, Middle-dose and Low-dose Chongcaoshenchacapsule group and fosinopril group. The HMCs induced by high glucose wereadopted to study. The normal control group HMCs were cultured with normalrat serum RPMI-1640 culture solution under normal glucose condition, highglucose group HMCs were cultured with normal rat serum high glucoseRPMI-1640 culture solution, the high-dose, middle-dose and low-doseChongcaoshencha group HMCs were incubated with different concentrationof Chongcaoshencha capsule rat serum RPMI-1640 culture solution underhigh glucose condition.the fosinopril group HMCs were incubated withfosinopril rat serum RPMI-1640 culture solution under high glucosecondition. The FCS concentration of every group is 10％. After therespective intervention of 24 hours, 48 hours and 72 hours, the HMCsproliferation was assessed by MTT assay. After culturing 48 and 72 hours byadding different serum respectively, transforming growth factor-betal(TGF-β1) , Fibronectin (FN) , Collagen-Ⅳ(Col-Ⅳ) , laminin (LN)secretion was determined by ELISA. The real time PCR was used to detectthe expression of transforming growth factor beta 1mRNA (TGF-β1mRNA)and plasminogen activator inhibitor-1 mRNA (PAI-1 mRNA)
Result:
(1) The high-dose Chongcaoshencha capsule serum can inhibit theproliferation of mesangial cells under high glucose condition (30mmol/L) at 24h、48h and 72h (p＜0.05, p＜0.01) , and showed better effect than thefosinopril serum. The middle-dose and low-dose Chongcaosheneha capsulecan inhibit the proliferation of mesangial cells under high glucose condition(30mmol/L) at 48h and 72h (p＜0.05) . (2) TheTGF-β1 secretion of thehigh-dose and middle-dose Chongcaoshencha capsule group is lower thanthat of the high glucose group at 48h and 72h (p＜0.05, p＜0.01) . Thelow-dose Chongcaoshencha capsule and fosinopril can decrease the secretionof TGF-β1 at 72h (p＜0.05) . Chongcaoshencha capsule has better effect. (3)The secretion of Col-Ⅳof Chongcaoshencha capsule group and thefosinopril group is lower than that in the high glucose group at 48h and 72h(p＜0.05, p＜0.01) . (4) The secretion of FN and LN of the high-doseChongcaoshencha capsule group is lower than that in the high glucose groupat 48h and 72h (p＜0.05, p＜0.01 ) . The middle-dose and low-doseChongcaoshencha capsule serum and fosinopril serum can decrease thesecretion of FN、LN at 72h (p＜0.05, p＜0.01) . (5) The expression ofTGF-β1mRNA and PAI-1mRNA of the high-dose and middle-doseChongcaoshencha capsule group and the fosinopril group are lower than thatof the high glucose group, and the expression of high-dose Chongcaoshenehacapsule group is the lowest (p＜0.05)
Conclusion:
Chongcaoshencha capsule not only can inhibit high glucose-inducedproliferation of HMCs, but also can decrease the secretion of TGF-β1, FN,Col-Ⅳ, LN, and degrade the expression of TGF-β1mRNA and PAI-1mRNA inthe high glucose cultured condition, so to delay the progression of DN.
方法：首先采用血清药理学的方法制备虫草肾茶胶囊及福辛普利药物血清，再进行药物血清干预HMC的研究。将常规培养的HMC分为正常对照组、高糖组、虫草肾茶高、中、低剂量组、福辛普利组，采用高糖模型(即高糖刺激体外培养的系膜细胞)进行研究。正常对照组予10％正常大鼠FCS改良型RPMI-1640培养液培养干预，高糖组予10％正常大鼠FCS改良型RPMI-1640高糖培养液培养干预，虫草肾茶高、中、低剂量组分别予10％虫草肾茶胶囊高、中、低剂量含药血清改良型RPMI-1640高糖培养液培养干预，福辛普利组予10％福辛普利含药血清改良型RPMI-1640高糖培养液培养干预。分别在相应干预因素处理后，于培养的24h、48h及72h用MTT法检测各组细胞增殖的情况；于相应干预因素作用48h及72h后，用ELISA法检测细胞培养液上清中转化生长因子-β1(TGF-β1)、纤维连接蛋白(FN)、Ⅳ型胶原(Col-Ⅳ)、层粘连蛋白(LN)的含量；用实时定量PCR方法检测人肾小球系膜细胞转化生长因子-β1mRNA(TGF-β1mRNA)、纤维蛋白溶解酶原激活物抑制剂-1mRNA(PAI-1mRNA)的表达。
结果：
(1)虫草肾茶胶囊高剂量药物血清对高糖(30mmol／L)刺激下24h、48h和72h的HMC的增殖均有抑制作用(p＜0.05，p＜0.01)，其作用优于福辛普利药物血清。虫草肾茶胶囊中、低剂量药物血清对高糖刺激下48h和72h的HMC的增殖有抑制作用(p＜0.05)。
(2)在48h和72h时段，虫草肾茶胶囊高、中剂量组TGF-β1的分泌明显低于高糖组(p＜0.05，p＜0.01)，而虫草肾茶胶囊低剂量药物血清及福辛普利药物血清对72h时段TGF-β1的分泌有抑制作用(p＜0.05)。在抑制TGF-β1的分泌方面，虫草肾茶胶囊优于福辛普利。
(3)虫草肾茶胶囊高、中、低剂量组及福辛普利组48h及72h HMCⅣ型胶原的合成均低于高糖组(p＜0.05，p＜0.01)。
(4)虫草肾茶胶囊高剂量组细胞培养上清中FN、LN在48h时段和72h时段的分泌均低于高糖组(p＜0.05，p＜0.01)，而虫草肾茶胶囊中、低剂量药物血清及福辛普利药物血清在72h时段可减少细胞培养上清中FN、LN的分泌(p＜0.05，p＜0.01)。
(5)虫草肾茶胶囊高、中剂量组及福辛普利组TGF-β1mRNA和PAI-1mRNA表达均低于高糖组，且以虫草肾茶胶囊高剂量组表达最低(p＜0.05)。
结论：虫草肾茶胶囊可以抑制高糖刺激下HMC的增殖，降低高糖刺激下TGF-β1及细胞外基质(ECM)主要成分FN、LN、Col-Ⅳ的合成和分泌，下调高糖刺激下HMC TGF-β1mRNA及PAI-1mRNA的表达，起到延缓DN进展的作用。
Objective:
To investigate the effects of Chongcaoshencha capsule on humanmesangial cells cultured in vitro under high glucose condition and explorethe nephroprotective mechanism of Chongcaoshencha capsule for DN.
Methods:
We first get the rats serum with different concentration of Chongcaoshenchacapsule and fosinopril, and then study the effects of the serum onHMCs. The cultured HMCs were divided into normal control group, highglucose group, High-dose, Middle-dose and Low-dose Chongcaoshenchacapsule group and fosinopril group. The HMCs induced by high glucose wereadopted to study. The normal control group HMCs were cultured with normalrat serum RPMI-1640 culture solution under normal glucose condition, highglucose group HMCs were cultured with normal rat serum high glucoseRPMI-1640 culture solution, the high-dose, middle-dose and low-doseChongcaoshencha group HMCs were incubated with different concentrationof Chongcaoshencha capsule rat serum RPMI-1640 culture solution underhigh glucose condition.the fosinopril group HMCs were incubated withfosinopril rat serum RPMI-1640 culture solution under high glucosecondition. The FCS concentration of every group is 10％. After therespective intervention of 24 hours, 48 hours and 72 hours, the HMCsproliferation was assessed by MTT assay. After culturing 48 and 72 hours byadding different serum respectively, transforming growth factor-betal(TGF-β1) , Fibronectin (FN) , Collagen-Ⅳ(Col-Ⅳ) , laminin (LN)secretion was determined by ELISA. The real time PCR was used to detectthe expression of transforming growth factor beta 1mRNA (TGF-β1mRNA)and plasminogen activator inhibitor-1 mRNA (PAI-1 mRNA)
Result:
(1) The high-dose Chongcaoshencha capsule serum can inhibit theproliferation of mesangial cells under high glucose condition (30mmol/L) at 24h、48h and 72h (p＜0.05, p＜0.01) , and showed better effect than thefosinopril serum. The middle-dose and low-dose Chongcaosheneha capsulecan inhibit the proliferation of mesangial cells under high glucose condition(30mmol/L) at 48h and 72h (p＜0.05) . (2) TheTGF-β1 secretion of thehigh-dose and middle-dose Chongcaoshencha capsule group is lower thanthat of the high glucose group at 48h and 72h (p＜0.05, p＜0.01) . Thelow-dose Chongcaoshencha capsule and fosinopril can decrease the secretionof TGF-β1 at 72h (p＜0.05) . Chongcaoshencha capsule has better effect. (3)The secretion of Col-Ⅳof Chongcaoshencha capsule group and thefosinopril group is lower than that in the high glucose group at 48h and 72h(p＜0.05, p＜0.01) . (4) The secretion of FN and LN of the high-doseChongcaoshencha capsule group is lower than that in the high glucose groupat 48h and 72h (p＜0.05, p＜0.01 ) . The middle-dose and low-doseChongcaoshencha capsule serum and fosinopril serum can decrease thesecretion of FN、LN at 72h (p＜0.05, p＜0.01) . (5) The expression ofTGF-β1mRNA and PAI-1mRNA of the high-dose and middle-doseChongcaoshencha capsule group and the fosinopril group are lower than thatof the high glucose group, and the expression of high-dose Chongcaoshenehacapsule group is the lowest (p＜0.05)
Conclusion:
Chongcaoshencha capsule not only can inhibit high glucose-inducedproliferation of HMCs, but also can decrease the secretion of TGF-β1, FN,Col-Ⅳ, LN, and degrade the expression of TGF-β1mRNA and PAI-1mRNA inthe high glucose cultured condition, so to delay the progression of DN.
引文
1．钱国熙．糖尿病肾病．国外医学内科分册1998，25(12)；312
2.Sehoeklmann HO,Lang S,Sterzel RB.Regulation of mesangial cell Proliferation. Kidney Int,1999,56(4): 1199-1207
3．宋立群，金丽霞，宋业旭．虫草肾茶胶囊治疗糖尿病肾病的临床研究[J]．中华中医药学刊，2009，27(4)：679-680
4．吕仁和，赵进喜，王越．糖尿病肾病临床研究评述[J]．北京中医药大学学报，1994，17(2)：21
5．赵进喜，邓德强，李靖．糖尿病肾病相关中医病名考辨[J]．南京中医药大学学报，2005，21(5)：288-289
6．刘玉宁，陈以平．糖尿病肾病肾小球硬化症的中医病机探讨[J]新中医．2003．35(7)：8
7．林兰，张鸿恩，高齐健等降糖通脉软胶囊治疗糖尿病血管合并症的临床研究．中医杂志．1992．33(8)：59
8．高彦斌．易京红．中医药辨治糖尿病肾病100例临床分析．中医杂志，1991．32(7)：31
9．王秀珍．健脾固肾汤治疗早期糖尿病肾病40例[J]．浙江中医杂志，2004，39(8)：332
10．徐云生，李莹，程益春治疗糖尿病肾病及视网膜病变经验，山东中医杂志，1998，17(1)：32
11．屠伯言，俞中康，郑敏宇等，糖尿病肾病用补肾活血法治疗的临床与实验研究，上海中医药杂志，1991，(1)：1
12．刘金城，农一兵，活血化瘀法在糖尿病肾病治疗中的作用，北京中医[J]2001，20，(1)：18
13．任爱华，阚方旭．糖尿病肾病三焦辨治[J]．山东中医杂志，2000，19(6)：328
14．冯建春，倪青．时振声教授治疗糖尿病肾病经验述要[J]．辽宁中医杂志，1996，23(12)：534-535
15．张庚良．糖尿病肾病的辨证治疗[J]．河北中医，2005，27(8)：594-595
16．王国芝，张莉，屈云．糖尿病肾病的中西医结合治疗的临床研究[J]．现代中医药，2003，23(4)：36-38
17．赵东鹰．辨证论治结合西药治疗糖尿病肾病56例[J]．陕西中医，2007，28(4)：415-416
18．张珍先．糖尿病肾病的辨证论治[J]．光明中医，2006，1(21)：16
19．李肇晕，曲丽卿．糖尿病肾病的辨证论治[J]．时珍国医国药，2006，17(3)：448
20．陈挽澜．益气养阴化瘀法治疗早期糖尿病肾病62例[J]．湖南中医杂志，2006，22(2)：48
21．夏红梅，尹卫华，宋雅琴．益气滋阴活血化瘀法治疗早期糖尿病肾病30例[J]．江西中医药，2005(1)：30
22．李玉忠，孔祥英、卢笑辉．补肾固精法治疗早期糖尿病肾病60例[J]．山东中医药大学学报，2005，29(4)：289-290
23．申艳萍，盖引利，刘岩．自拟补肾活血汤治疗糖尿病肾病122例临床观察[J]．浙江中医杂志，2007，42(3)：145-146
24．陈军．益肾通络法治疗糖尿病肾病32例．湖北中医杂志，2002，24(11)：42
25．王悦芳，苑彦娟，王彦刚．健脾补肾化瘀通络法治疗糖尿病肾病58例疗效分析．中华实用中西医结合杂志，2003，3(16)：782-783
26．刘承琴，赵建群．滋肾健脾化瘀方治疗早期糖尿病肾病41例．山东中医杂志．2003，22(11)：648-649
27．苗桂珍．活血化痰方治疗2型糖尿病26例[J]．中国中西医结合杂志，2001，21(2)：144-145
28．许陵冬，郭惠芳．化痰活血通络法治疗糖尿病肾病82例．辽宁中医杂志，2000，27(1)：17-18
29．孙伟，何伟明．糖尿病肾病蛋白尿的中医药治疗体会．江苏中医药，2002，23(5)：18-19
30．卜擎燕．清热化瘀法治疗糖尿病肾病临床疗效观察．时珍国医国药，2002，13(12)：715-716
31．谢立群．活血化瘀法治疗糖尿病肾病80例疗效观察[J]．时珍国医国药，2001，12(8)：721
32．张新义，傅文录．疏风凉血化瘀法治疗糖尿病肾病30例．现代中西医结合杂志，2004，13(3)：332-333
33．肖连坤，杨成，杨集群．活血化瘀利水泻毒法治疗糖尿病肾病32例．吉林中医药，2003，23(11)：21
34．林芝韵，侯卫国，何立群，等．通络益肾合剂治疗糖尿病肾病临床观察．上海中医药杂志，2000，3：10-11
35．赵贤俊，邓悦，李光善，等．解毒通络保肾散治疗糖尿病肾病114例分析，中医药学刊，2003，21(6)：949-950
36．计磊，潘美妍，王璐．黄芪注射液治疗糖尿病肾病的疗效[J]．实用医药杂志，2006，23(4)：439
37．冯毅，冯烈．黄芪对糖尿病大鼠肾脏保护作用的机制[J]．实用医学杂志，2006，22(21)：2457-2459
38．施萍，李正．黄芪在糖尿病肾病治疗中降低尿微量白蛋白的作用[J]．现代临床医学，2005，31(2)：89-90
39．唐宗琼．大黄及其复方治疗糖尿病肾病的研究进展．四川生理科学杂志2004：26(4)：157-159
40．王慧芳，马骏，陈国庆，等．大黄对早期糖尿病肾病患者肾脏血流动力学的影响[J]．铁道医学，2001，99(5)：320-321
41．杨淑兰，赵晓春．大黄对老年2型糖尿病尿蛋白排泄率的影响[J]．长治医学院学报，2001，14(3)：177-178
42．赵凡，区转焕．葛根素注射液治疗早期糖尿病肾病的疗效[J]．实用临床医学，2006，7(6)：27-28
43．杨明正，张小如．决明子对糖尿病大鼠肾组织NF-κB活化的影响[J]．浙江中西医结合杂志，2006，16(3)：149-150
44．李忠亮，常冰玲．血塞通治疗糖尿病肾病的疗效观察[J]．中国误诊学杂志，2005，5(11)：33-34
45．张义军，康仔，张伟栋．泽兰对家兔血流变性及球结膜微循环的影响[J]．微循环学杂志，1996，6(2)：31-32
46．冉颖卓．虫草菌制剂对2型糖尿病早期肾病30例的干预治疗[J]．陕西中医，2006，27(3)：309-310
47．孙建红，何戒华，任传路．虫草制剂和开搏通对糖尿病大鼠肾脏功能和形态影响的对比研究[J]．徐州医学院学报，2000，20(6)：450-453
48．余江毅，黄蜀葵花醇提物治疗糖尿病肾病的临床观察，中国中西医结合杂志，1995．15(5)：263
49．毛炜，郭立中，庞嶷，等．雷公藤药物血清体外对肾小球系膜细胞增殖及其分泌IL-6的影响[J]．第四军医大学学报，2006，27(13)：1204
50．王啸飞，王洪语．川芎嗪对早期糖尿病肾病的治疗作用[J]．实用中医内科杂志，2005，20(2)：78
51．汪霞，黎七雄．川芎嗪对脂多糖诱导大鼠肾小球系膜细胞增殖及细胞间黏附因子-1表达的影响[J]．中国临床药理学与治疗学，2004，9(4)：420-422
52．董砚虎，逢力男，王秀军，等，黄芩甙治疗糖尿病肾病疗效观察，山东医药[J]，1998，38(12)：7
53．钟生维，卢远航，银杏叶提取物对早期糖尿病肾病血黏度及尿蛋白的影响。新医学[J]．2000，31，(9)：533
54．苏宁，连至诚．糖肾康合剂对实验性大鼠糖尿病肾病的预防作用．中药新药与临床药理，2003，14(4)：233-236
55．曹和欣．糖肾宁对早期糖尿病肾病大鼠肾脏高滤过的影响[J]．上海中医药杂志，2001，35(5)：19
56．韩文霞．糖。肾康改善糖尿病肾病早期肾血流动力学异常及及一氧化氮水平的研究．山东中医药大学学报，2003，27(4)：266-269
57．祁忠华，林善锬，黄宇峰．黄芪改善糖尿病早期肾血流动力学异常的研究．中国糖尿病杂志，1999，7(3)：147-149
58. Lam hc.lee JK.Chiang ht.Does endothelin play a role in the path of early diabetic nephropathy.J Cardiovasc Pharame. 1995.26:479
59．倪海洋，罗苏生，邵国民，等．刺五加注射液对早期糖尿病肾脏病变及血浆、尿内皮素的影响[J]．中国中西医结合杂志，2001，21(2)：105
60．黄焱，陈少强，张更，等．川芎嗪联合氨基胍对糖尿病肾病大鼠肾脏一氧化氮的影响．中国中西医结合肾病杂志，2003，4(5)：265-267
61．仝小林，周水平，朴信映，等．络通对糖尿病大鼠肾脏的保护作用及机理研究．中国中医基础医学杂志，2001，7(12)：35-37
62．侯卫国，王琛，唐英，等．血府逐瘀胶囊治疗糖尿病肾病的临床观察[J]．上海中医药杂志，2006，40(6)：35
63．肖黎，丁樱，张红敏，等．肾必宁冲剂对肾小球系膜细胞凋亡及基因表达的影响．上海中医药大学学报，2001，15(3)：35-37
64．沈雯，陆福明，顾勇，等．黄答素对高糖诱导近端肾小管上皮细胞外基质及转化生长因子β1表达的影响．中华肾脏病杂志，2003，19(3)：173-176
65．耿建国，王长松．真武汤对人胎肾小球系膜细胞外基质作用的实验研究．中医杂志，2000，41(11)：686-687
66．曹晓华，毕静，郑静飞，等．糖肾通络宁对糖尿病大鼠早期肾脏病变影响的实验研究．中医药学刊，2003，21(10)：1716-1717
67．朱加明，刘志红，黎磊石，等．大黄酸对db/db小鼠糖尿病肾病疗效的观察．肾脏病与透析肾移植杂志，2002，11(1)：3-11
68．李长天，陈雁飞·葛根素对糖尿病大鼠肾脏糖基化终产物和转化生长因子-β1表达的影响[J]．中国中医药信息杂志，2006，13(3)：36-38
69．唐红，徐蓉娟，李红，等．中药调控血小板衍化生长因子逆转早期糖尿病肾病机制的实验研究．中国中西医结合杂志，2003，4(9)：510-513
70．黄焱，陈少强，张更，等．川芎嗪联合氨基胍对糖尿病大鼠肾脏血管内皮细胞生长因子表达和影响．中西医结合学报，2004，2(1)：39-41
71．牟娜，张庆怡，倪兆慧，等．黄芪对高糖作用下肾间质成纤维细胞表达HGF的影响．中国中西医结合肾病杂志，2002，1(3)：7-9
72．龚学忠，贾秀琴，李雪梅，等．加味参芪地黄汤对大鼠系膜细胞分泌IL-1、IL-6的影响．深圳中西医结合杂志，2001，11(2)：78-80
73．郑士荣，张景红，朱宇清，等．地灵丹对大鼠糖尿病肾病影响的实验研究[J]．上海中医药杂志，2006，40(8)：62
74．陈雪功，周雪梅，张琼玉，等．冬梅饮对早期糖尿病肾病大鼠肾组织非酶糖基化终产物影响的实验研究[J]．中国中医基础医学杂志，2006，12(11)：829
75．郭妍，周传伟，许健．葛根素对糖尿病大鼠肾脏非酶糖基化和氧化应激的抑制作用．江苏医药杂志2003，29(9)：669-670
76．刘长山，李萍．黄芩甙对糖尿病患者红细胞醛糖还原酶活性及早期糖尿病肾病的影响[J]．中国老年学杂志，2001，21(5)：334
77. Wild S,Roglic G, Sicree R,Green A,King H.Global burden of diabetes mellitus in the year2000.Globall Burden Disease,Geneva;WHO,2003
78. American Diabetes Association. Diabetic nephropathy. Diabetes Care, 2003, 26 (Suppl 1): S94-S98
79. Berger M,Mnks D,Wanner C,et al.Diabetic nephropathy: an in-herited disease or just a diabetic complication? [J].Kidney Blood Press Res, 2003, 26(3): 143-154
80. Xu J, Lee ET, Devereux RB A longitudinal study of risk factors for incident album inuria in diabetic American lndians: The Strong Heart Study. Am J Kidney Dis. 2008, 51:415-424
81. DERUBERTIS FR,CRAVEN PA.Activation of protein k inase C in glomerular cells in diabetes.mechanism and potential links to the pathogenesis of diabetic glomerulo pathy [J].Diabetes,2005,43(3): 1
82. HAN B.Effect observation on treating diabetic nephropathy with kidney-tonifying granule connect with lotensin and tripterygium wilfordi glyeoside tablet[J].China Medical Engineering,2006,14(2): 137-142.Chinese
83．陈小敏，杨香玖．2型糖尿病肾病的相关危险因素．福建医科大学学报2005，39(2)；207
84. Adler A I,Stevens RJ,Manley SE,et al.Development and progression of nephro pathy in type 2 diabetes:the United Kingdom Prospective Diabetes Study (UKPDS64) [J].Kidney Int,2003,63(1):225-232
85．全春兰．糖尿病肾病的预防和护理进展．解放军护理杂志2004年12月，21(12)：135
86．王娜等．糖尿病肾病的研究现状．国外医学内分泌医学分册2004，24(2)；354
87．马文，沈善康，王薇，等．江汉油田成人糖尿病患病率及其危险因素的流行病学调查．临床内科杂志2004，21(7)；476
88．曲晓璐．1718例2型糖尿病患者糖尿病肾病发病率及其中医证型分布特点．中国中西医结合肾病杂志2003，4(12)；453
89. Ansquer JC,Foucher C,Rattier S,et al.(2005).Fenofibrate reduces progression to microalbuminuria over 3 years in a Placebo-controlled study in type 2 diabetes:results from the Diabetes Atheroselerosis Intervention Study(DAIS)[J].Am J Kidney Dis 45 (3):485-93
90．金世鑫．美国糖尿病学会2007糖尿病诊疗标准(三)[J]．中国糖尿病杂志，2007，15(4)：附录
91. Baggio B,Budakovie A,Dalla Vestra M,etal.Effects of cigarette smoking on glomerular structure and function in type 2 diabetic patients[J].J Am Soe Nephrol, 2002,13(11):2730-6
92．赵日方．2型糖尿病合并早期糖尿病肾病的相关危险因素分析．长治医学院学报2007，21(4)；259
93. Lane JT.Microalbuminuria as a maker of cardiovascular and renal risk in type 2 diabetes mellitus:a temporal perspective.Am J Physiol Renal Physiol, 2004, 286; F442-F450
94. American Diabetes Association.Diabetic Nephropathy.Diabetes Care,2004,26; 94s-98s
95．王克勤．糖尿病肾病发病机制及治疗新方向．医生论坛2003，18(21)；452
96. Gall MA,Hougaard,Borch Johnsen K,et al.Risk factors for devopment of incipient and overt diabetic nephropathy in patients Withnon-insulindependent diabetes mellitus: prospective, observational incipient and overt diabetic study[J].BMJ,1997, 314;7883-7888
97. Hodgkinson AD,M ill ward BA, Demaine AG. Polymorphism of the glucose transporter (GLUT1) gene are associated with diabetic nephropathy[J].Kidney Int, 2001, 59(3): 985
98. Lee L K,Meyer T W, Pollock A S,et al.Endothekial cell injury initiates glomerular sclerosis in the rat remnant kidney.J Clon Invest, 1995,96(2):953-964
99. Sharma K,Ziyadeh F N.Hyperglycemia and diabetic kidney disease.The case for transforming growth factor-beta as a key mediator.Diabetes,1995,44,44(10):1139-1146
100. Singh R,Alavi N,Singh A K,et al.Role of angiotensin Ⅱ in glucoseinduced inhibition of mesangial matrix degradation.Diadetes, 1999,48(10):2066-2073
101. Isono M,Mogyorosi A,Han D C,et al.Stimulation of TGF-beta type Ⅱ receptor by high glucose in mouse mesangial cells and in diabetic kidney.Am J Physiol Renal Physiol,2000,278(5):F830-838
102. Wendt TM,Tanji N,Guo J,et al.RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy.Am J Pathol,2003,162(4):1123-37
103. Oh J H,Ha H,Yu M R,et al.Seqiential effects of high glucose on messangial cell transforming growth factor-beta 1 and fibronectin synthesis.Kidney Int, 1998, 54: 1872-8
104.Lupia E,Elliot SJ,Lenz O,et al.IGF-ldecrease Collagen degradation in diabetic NOD Mesangial cells:implications for diabetic nephropathy. Diabetes, 1999,48: 1638-1644
105.Browniee M.Negative consequences of glycation.Metabolism.2000;149:9-13
106.Raecah D,Coste T, Cameron NE,et al.Effect of the aldose reductase inhibitor tolrestat on nerve conduction velocity Na/K ATP ase activity,and polyols in red blood cells.scialie nerve kidney cortex,and kidney medulla of diabetic rats.J Diabetes Complications, 1998, 12:154-162
107.Okada S, Shikata K. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes[J].Diabetes, 2003, 52(10): 2586
108.Jin Y, Moriya T, Tanaka K, et al. Glumerular hyperfiltration in no-proteinuric and non-hypertensive Janpanese type 2 diabetic patients. Diabetes Rrs Clin Pract, 2005: 23
109.Remuzzi G, Perico N, Macia M,et al. The role of renin-angio-tensin-aldosterone system in the progression of chronic kidney disease[J].Kidney Int, 2005, 99(Suppl): S57-S65
110.American Diabetes Association.[J].Diabetes Care, 2004, 27(Suppl1): S79-83
111．叶山东，朱禧星．临床糖尿病学．合肥：安徽科学技术出版社，2005．194
112.Mimran A, Alfaro V.Candesartan:nephroProtective effects and treatment of. diabetic nephropathy.Drugs Today,2003:39:439-50
113.Rachmani R, Slavachevsky I, Amit M, et al.[J].Diabetic Med, 2004, 21(5): 471-475
114．向群，杨春云，姚强，等．低分子肝素钠对糖尿病肾病尿蛋白作用探讨．新医学，2004，35(3)：167
115.Moriyama T, Oka K, Ueda H, et al.[J].Clin Exp Nephrol, 2004, 8(3): 230-236
116.Inoue T, Okdaa H,Kobayashi T et al.Hepatocyte growth factor counteracts transforming growth factor-betal,through attenuation of connective tissue growth factor induction,and prevents renal fibrogenesis in 5/6 nephrectomizedmice. FASEBJ 17,2003:268-270
117.Paleologo G, Tregnaghi C, Bianchi AM, et al.[J].Transplant Proc, 2004, 36(3):591-596
118.刘新民,潘长玉,张达青,等.实用内分泌学[M].北京:人民军医出版社,2004.1471
119.Schnaper HW,Hayashida T,Hubchak SC,et al.TGF-beta signal transduction and mesangial cell fibrogenesis.Am J Physiol Renal Physiol,2003,284:F243-F252
120.Wolf G,Ziyadeh FN.Molecular mechanisms of diabetic renal hypertrophy [J].Kidney Int,1999,56(2):393-405
121.Branton MH,Kopp JB.TGF-beta and fibrosis.Microbes Infect,1999,1:1349-1365
122.Sharma K,Jin Y,Guo J,et al.Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice.Diabetes,1996,45:522-530
123.Hoshi S,Shu Y,Yoshida F,et a.Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats[J].Lab Invest,2002,82(1):25-35
124.Nakamura T,Ushiyama C,Suzuki S,et al.Urinary excretion of podocytes in patients with diabetic nephropathy[J].Neprol Dial Transplant 2000;15(9): 1379- 1383
125.Ina K,Kitamura H,Tatsukawa S,et al.Transformation of interstitial fibroblasts and tubulointerstitial fibrosis in diabetic nephropathy[J].Med Electron Microsc,2002, 35(2):8-96
126.Richard E.,Gilbert,Alison Cox,et al.Expression of transforming grow the factor-|31 and type IV collagen in the renal tubulo interstitium in experimental diabetes.Diabetes,1998,47:414
127.Poncelete AC,et al.Am J Phisiol,1998;275:458-466
128.Esaka Y,et al.J Clin Invest,1993;92:2597-2601
129.Suzuki M,Akimoto K,Hattori Y.Glucose upregulates plasminogen activator inhibitor-1 gene expression in vascular smooth muscle cells.Life Sci.2002;72(1):59-66
130.Auzuki M,A kimito K,Hattoi Y.Glucose upregulates plasminogen activator-1 gene expression in vascular smooth muscle cells.Life Sci,2002,72:59-66
131.Mcfarlane SL,Sowers JK,et al.Aldosterone function in diabetes mellitus:effects on cardiovascular and renal disesase.J Clin Endocrino.Metab,2003,85:516-523
132.Wolf G.Link between angiotensin Ⅱ and TGF-βin the kidney[J].Electrolyte Metab, 1998,25:174
133.Goldberg HJ, Scholey J,Fantus I G, et al. Glucosamine activates the plasminogen activator inhibitor-1 gene promoter through SP1 DNA binding sites glomerular mesangial cell[J].Diabetes,2000,49:863-871
134.Samad F,Yamamoto K,Loskutoff DJ,et al.Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo:induction by tumor necrosis factor-αand lipopolysaccharide[J].Clin Invest, 1996,97(1):37-46
135.Agostino G, Tonoli M,Deorsola B,et al.PAI-1 release fromhuman adipose tissue is stimulated by TNF-alpha[J].Thromb Haemost, 1997,77 [Suppl] :749
136.Liu C, Yao J, de Belle I, et al. The transcription factor EGR-1 suppress transformation of human fibrosarcoma HT1080 cells by coordinated induction of TGF-β,FN and PAI-1[J].J Biol Chem,1999,274:4400-4411
137.Wolf G, Ziyadeh FN.Kidney Int, 1999;56:393
138.Mauer SM,Steffes MW, Brown DM. Strueture functional relation in diabetic nephropathy .J Clin Invest, 1994;74:1143-1154
139．高玉洁，李冬梅．高糖对大鼠肾小球系膜细胞分泌t-PA及PAI-1的实验影响[J]．放射免疫学杂志，2004，17(2)：267
140.Ziyadeh f N,HAN D C,COHEN J A,et al.Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cells: involvement of the transforming growth factor-beta system [J].Kidney Int,1998,53(3):631-638
141.Shultz PJ,Raij L. The glomerular mesangiurn:Role in initiation and Progression of renal injury.Am J Kidney Dis 1991;17:8
142.Sinonson MS,Dunn INJ.Endothelin peptides:A possible role in glomerular imflammation,Lab Invest 1991;64:1
143.Murphy M,Godson C,Cannon S,et al. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells[J].J Biol Chem, 1999,274:5830
144.Kim SI.Han DC,Lee HB. Lovastatin inhibitstrans forming growth factor-81 expression in diabetic rat glomeruli and cultured rat mesangial cells[J].J Am Soc Nephrol,2000.11(1):80-87
145．张燕．霉酚酸酯防治早期糖尿病肾病的实验研究．2007：22
146．王箔，张军平．中药血清药理学实验方法研究概况[J]．天津中医药，2005，22(1)：86-88
147.Bao J F,Liu G Q.Study of the effect of NLZB on PC12 cell injury via serological pharmacological methods[J].J China pharm Univ(中国药科大学学报), 2000, 31 (2):126-129
148．蒙一纯，丁霞，贲长恩等，中药血清药理学应用研究展望[J]．北京中医药大学学报，1999，22(4)：42-43
149．金百胜．芦荟提取物防治糖尿病肾病的实验研究及其保护机理的初步探讨．2007：40
150.Cosio FG, et al.Effects of high glucose concentrations on human mesangial cell proliferation.J Am Soc Nephrol 1995;5(8):1600-1609
151．高俊瑞，马健飞，张全．Ⅳ型胶原与肾小球疾病[J]．临床荟萃，2001，16(12)：569-571．
152．龙若庭，何泽云．怡肾汤对5/6肾切除大鼠残肾组织形态与Co-Ⅳ及MMP-2的干预作用[J]．中国中西医结合肾病杂志，2006，7(6)：324-327
153．张月娥．纤维连接蛋白在肾小球硬化过程中的演变情况观察[J]．中华病理杂志，1987，16(1)：36-38
154.Makino T,Ono T, Muso E,et al.inhibitory effects of rosmarinic acid on the proliferation of cultured murine mesangial cells.Nephrol Dial Transplant, 2000, 15 (8):1140-1145
155．刘广建，黄荣桂，郑兴中．肾茶对糖尿病大鼠肾脏的保护作用及其机制研究[J]．中国中西医结合肾病杂志，2007，8(1)：32-34
156．任现志，汪受传，翟文生．水蛭治疗系膜增生性肾小球肾炎的探讨[]．辽宁中医杂志，2005，32(3)：244
157.Weston BS,Wahab NA,Roberts T, et al.Bacitracin inhibits fibronectin matrix assembly by mesangial cells in high glucose[J].Kidney Int,2001,60(5):1756-1764
158.Singh R, Song RH,Alavi N,et al.High glucose decreases matrix Metalloproteinase-2 activity in rat mesangial cells via transforming growth factor-beta [J].Exp Nephrol, 2001,9(4):249-257
159．张燕．霉酚酸醋防治早期糖尿病肾病的实验研究．2007：31
160.Mackay K,Stiker LJ,Stauffer JW, et al.Transforming growth factor-B:murlne glomerular receptors and responses of isolaled glomerular cells.J Clin Invest, 1989: 83(4):1160-1167
161.Li YJ,Liu ZH,Liu D,Zhu JM,Guo XH,Li LS.High glucose induced mesangial cell transforming growth factorβ1 synthesis is mediated by upregulated hexosamine biosynthesis pathway.Chinese journal of nephrology dialysis and transplantation. 2000:9(4):303-310
162.Eddy AA,Molecular basis of renal fibrosis.Pediatr Nephrol 2000;15(3-4):290-301.
163.Datta PK,Blake MC,Moses HL.Regulation of plasminogen activator inhibitor-1 expression by transforming growth factor-beta-induced physical and functional interactions between smads and Sp1.J Biol Chem2000;275(51):40014-40019
164．柳刚．糖尿病肾病大鼠肾脏细胞因子表达的变化及丹参/氮沙坦干预研究．2005：61
2.Sehoeklmann HO,Lang S,Sterzel RB.Regulation of mesangial cell Proliferation. Kidney Int,1999,56(4): 1199-1207
3．宋立群，金丽霞，宋业旭．虫草肾茶胶囊治疗糖尿病肾病的临床研究[J]．中华中医药学刊，2009，27(4)：679-680
4．吕仁和，赵进喜，王越．糖尿病肾病临床研究评述[J]．北京中医药大学学报，1994，17(2)：21
5．赵进喜，邓德强，李靖．糖尿病肾病相关中医病名考辨[J]．南京中医药大学学报，2005，21(5)：288-289
6．刘玉宁，陈以平．糖尿病肾病肾小球硬化症的中医病机探讨[J]新中医．2003．35(7)：8
7．林兰，张鸿恩，高齐健等降糖通脉软胶囊治疗糖尿病血管合并症的临床研究．中医杂志．1992．33(8)：59
8．高彦斌．易京红．中医药辨治糖尿病肾病100例临床分析．中医杂志，1991．32(7)：31
9．王秀珍．健脾固肾汤治疗早期糖尿病肾病40例[J]．浙江中医杂志，2004，39(8)：332
10．徐云生，李莹，程益春治疗糖尿病肾病及视网膜病变经验，山东中医杂志，1998，17(1)：32
11．屠伯言，俞中康，郑敏宇等，糖尿病肾病用补肾活血法治疗的临床与实验研究，上海中医药杂志，1991，(1)：1
12．刘金城，农一兵，活血化瘀法在糖尿病肾病治疗中的作用，北京中医[J]2001，20，(1)：18
13．任爱华，阚方旭．糖尿病肾病三焦辨治[J]．山东中医杂志，2000，19(6)：328
14．冯建春，倪青．时振声教授治疗糖尿病肾病经验述要[J]．辽宁中医杂志，1996，23(12)：534-535
15．张庚良．糖尿病肾病的辨证治疗[J]．河北中医，2005，27(8)：594-595
16．王国芝，张莉，屈云．糖尿病肾病的中西医结合治疗的临床研究[J]．现代中医药，2003，23(4)：36-38
17．赵东鹰．辨证论治结合西药治疗糖尿病肾病56例[J]．陕西中医，2007，28(4)：415-416
18．张珍先．糖尿病肾病的辨证论治[J]．光明中医，2006，1(21)：16
19．李肇晕，曲丽卿．糖尿病肾病的辨证论治[J]．时珍国医国药，2006，17(3)：448
20．陈挽澜．益气养阴化瘀法治疗早期糖尿病肾病62例[J]．湖南中医杂志，2006，22(2)：48
21．夏红梅，尹卫华，宋雅琴．益气滋阴活血化瘀法治疗早期糖尿病肾病30例[J]．江西中医药，2005(1)：30
22．李玉忠，孔祥英、卢笑辉．补肾固精法治疗早期糖尿病肾病60例[J]．山东中医药大学学报，2005，29(4)：289-290
23．申艳萍，盖引利，刘岩．自拟补肾活血汤治疗糖尿病肾病122例临床观察[J]．浙江中医杂志，2007，42(3)：145-146
24．陈军．益肾通络法治疗糖尿病肾病32例．湖北中医杂志，2002，24(11)：42
25．王悦芳，苑彦娟，王彦刚．健脾补肾化瘀通络法治疗糖尿病肾病58例疗效分析．中华实用中西医结合杂志，2003，3(16)：782-783
26．刘承琴，赵建群．滋肾健脾化瘀方治疗早期糖尿病肾病41例．山东中医杂志．2003，22(11)：648-649
27．苗桂珍．活血化痰方治疗2型糖尿病26例[J]．中国中西医结合杂志，2001，21(2)：144-145
28．许陵冬，郭惠芳．化痰活血通络法治疗糖尿病肾病82例．辽宁中医杂志，2000，27(1)：17-18
29．孙伟，何伟明．糖尿病肾病蛋白尿的中医药治疗体会．江苏中医药，2002，23(5)：18-19
30．卜擎燕．清热化瘀法治疗糖尿病肾病临床疗效观察．时珍国医国药，2002，13(12)：715-716
31．谢立群．活血化瘀法治疗糖尿病肾病80例疗效观察[J]．时珍国医国药，2001，12(8)：721
32．张新义，傅文录．疏风凉血化瘀法治疗糖尿病肾病30例．现代中西医结合杂志，2004，13(3)：332-333
33．肖连坤，杨成，杨集群．活血化瘀利水泻毒法治疗糖尿病肾病32例．吉林中医药，2003，23(11)：21
34．林芝韵，侯卫国，何立群，等．通络益肾合剂治疗糖尿病肾病临床观察．上海中医药杂志，2000，3：10-11
35．赵贤俊，邓悦，李光善，等．解毒通络保肾散治疗糖尿病肾病114例分析，中医药学刊，2003，21(6)：949-950
36．计磊，潘美妍，王璐．黄芪注射液治疗糖尿病肾病的疗效[J]．实用医药杂志，2006，23(4)：439
37．冯毅，冯烈．黄芪对糖尿病大鼠肾脏保护作用的机制[J]．实用医学杂志，2006，22(21)：2457-2459
38．施萍，李正．黄芪在糖尿病肾病治疗中降低尿微量白蛋白的作用[J]．现代临床医学，2005，31(2)：89-90
39．唐宗琼．大黄及其复方治疗糖尿病肾病的研究进展．四川生理科学杂志2004：26(4)：157-159
40．王慧芳，马骏，陈国庆，等．大黄对早期糖尿病肾病患者肾脏血流动力学的影响[J]．铁道医学，2001，99(5)：320-321
41．杨淑兰，赵晓春．大黄对老年2型糖尿病尿蛋白排泄率的影响[J]．长治医学院学报，2001，14(3)：177-178
42．赵凡，区转焕．葛根素注射液治疗早期糖尿病肾病的疗效[J]．实用临床医学，2006，7(6)：27-28
43．杨明正，张小如．决明子对糖尿病大鼠肾组织NF-κB活化的影响[J]．浙江中西医结合杂志，2006，16(3)：149-150
44．李忠亮，常冰玲．血塞通治疗糖尿病肾病的疗效观察[J]．中国误诊学杂志，2005，5(11)：33-34
45．张义军，康仔，张伟栋．泽兰对家兔血流变性及球结膜微循环的影响[J]．微循环学杂志，1996，6(2)：31-32
46．冉颖卓．虫草菌制剂对2型糖尿病早期肾病30例的干预治疗[J]．陕西中医，2006，27(3)：309-310
47．孙建红，何戒华，任传路．虫草制剂和开搏通对糖尿病大鼠肾脏功能和形态影响的对比研究[J]．徐州医学院学报，2000，20(6)：450-453
48．余江毅，黄蜀葵花醇提物治疗糖尿病肾病的临床观察，中国中西医结合杂志，1995．15(5)：263
49．毛炜，郭立中，庞嶷，等．雷公藤药物血清体外对肾小球系膜细胞增殖及其分泌IL-6的影响[J]．第四军医大学学报，2006，27(13)：1204
50．王啸飞，王洪语．川芎嗪对早期糖尿病肾病的治疗作用[J]．实用中医内科杂志，2005，20(2)：78
51．汪霞，黎七雄．川芎嗪对脂多糖诱导大鼠肾小球系膜细胞增殖及细胞间黏附因子-1表达的影响[J]．中国临床药理学与治疗学，2004，9(4)：420-422
52．董砚虎，逢力男，王秀军，等，黄芩甙治疗糖尿病肾病疗效观察，山东医药[J]，1998，38(12)：7
53．钟生维，卢远航，银杏叶提取物对早期糖尿病肾病血黏度及尿蛋白的影响。新医学[J]．2000，31，(9)：533
54．苏宁，连至诚．糖肾康合剂对实验性大鼠糖尿病肾病的预防作用．中药新药与临床药理，2003，14(4)：233-236
55．曹和欣．糖肾宁对早期糖尿病肾病大鼠肾脏高滤过的影响[J]．上海中医药杂志，2001，35(5)：19
56．韩文霞．糖。肾康改善糖尿病肾病早期肾血流动力学异常及及一氧化氮水平的研究．山东中医药大学学报，2003，27(4)：266-269
57．祁忠华，林善锬，黄宇峰．黄芪改善糖尿病早期肾血流动力学异常的研究．中国糖尿病杂志，1999，7(3)：147-149
58. Lam hc.lee JK.Chiang ht.Does endothelin play a role in the path of early diabetic nephropathy.J Cardiovasc Pharame. 1995.26:479
59．倪海洋，罗苏生，邵国民，等．刺五加注射液对早期糖尿病肾脏病变及血浆、尿内皮素的影响[J]．中国中西医结合杂志，2001，21(2)：105
60．黄焱，陈少强，张更，等．川芎嗪联合氨基胍对糖尿病肾病大鼠肾脏一氧化氮的影响．中国中西医结合肾病杂志，2003，4(5)：265-267
61．仝小林，周水平，朴信映，等．络通对糖尿病大鼠肾脏的保护作用及机理研究．中国中医基础医学杂志，2001，7(12)：35-37
62．侯卫国，王琛，唐英，等．血府逐瘀胶囊治疗糖尿病肾病的临床观察[J]．上海中医药杂志，2006，40(6)：35
63．肖黎，丁樱，张红敏，等．肾必宁冲剂对肾小球系膜细胞凋亡及基因表达的影响．上海中医药大学学报，2001，15(3)：35-37
64．沈雯，陆福明，顾勇，等．黄答素对高糖诱导近端肾小管上皮细胞外基质及转化生长因子β1表达的影响．中华肾脏病杂志，2003，19(3)：173-176
65．耿建国，王长松．真武汤对人胎肾小球系膜细胞外基质作用的实验研究．中医杂志，2000，41(11)：686-687
66．曹晓华，毕静，郑静飞，等．糖肾通络宁对糖尿病大鼠早期肾脏病变影响的实验研究．中医药学刊，2003，21(10)：1716-1717
67．朱加明，刘志红，黎磊石，等．大黄酸对db/db小鼠糖尿病肾病疗效的观察．肾脏病与透析肾移植杂志，2002，11(1)：3-11
68．李长天，陈雁飞·葛根素对糖尿病大鼠肾脏糖基化终产物和转化生长因子-β1表达的影响[J]．中国中医药信息杂志，2006，13(3)：36-38
69．唐红，徐蓉娟，李红，等．中药调控血小板衍化生长因子逆转早期糖尿病肾病机制的实验研究．中国中西医结合杂志，2003，4(9)：510-513
70．黄焱，陈少强，张更，等．川芎嗪联合氨基胍对糖尿病大鼠肾脏血管内皮细胞生长因子表达和影响．中西医结合学报，2004，2(1)：39-41
71．牟娜，张庆怡，倪兆慧，等．黄芪对高糖作用下肾间质成纤维细胞表达HGF的影响．中国中西医结合肾病杂志，2002，1(3)：7-9
72．龚学忠，贾秀琴，李雪梅，等．加味参芪地黄汤对大鼠系膜细胞分泌IL-1、IL-6的影响．深圳中西医结合杂志，2001，11(2)：78-80
73．郑士荣，张景红，朱宇清，等．地灵丹对大鼠糖尿病肾病影响的实验研究[J]．上海中医药杂志，2006，40(8)：62
74．陈雪功，周雪梅，张琼玉，等．冬梅饮对早期糖尿病肾病大鼠肾组织非酶糖基化终产物影响的实验研究[J]．中国中医基础医学杂志，2006，12(11)：829
75．郭妍，周传伟，许健．葛根素对糖尿病大鼠肾脏非酶糖基化和氧化应激的抑制作用．江苏医药杂志2003，29(9)：669-670
76．刘长山，李萍．黄芩甙对糖尿病患者红细胞醛糖还原酶活性及早期糖尿病肾病的影响[J]．中国老年学杂志，2001，21(5)：334
77. Wild S,Roglic G, Sicree R,Green A,King H.Global burden of diabetes mellitus in the year2000.Globall Burden Disease,Geneva;WHO,2003
78. American Diabetes Association. Diabetic nephropathy. Diabetes Care, 2003, 26 (Suppl 1): S94-S98
79. Berger M,Mnks D,Wanner C,et al.Diabetic nephropathy: an in-herited disease or just a diabetic complication? [J].Kidney Blood Press Res, 2003, 26(3): 143-154
80. Xu J, Lee ET, Devereux RB A longitudinal study of risk factors for incident album inuria in diabetic American lndians: The Strong Heart Study. Am J Kidney Dis. 2008, 51:415-424
81. DERUBERTIS FR,CRAVEN PA.Activation of protein k inase C in glomerular cells in diabetes.mechanism and potential links to the pathogenesis of diabetic glomerulo pathy [J].Diabetes,2005,43(3): 1
82. HAN B.Effect observation on treating diabetic nephropathy with kidney-tonifying granule connect with lotensin and tripterygium wilfordi glyeoside tablet[J].China Medical Engineering,2006,14(2): 137-142.Chinese
83．陈小敏，杨香玖．2型糖尿病肾病的相关危险因素．福建医科大学学报2005，39(2)；207
84. Adler A I,Stevens RJ,Manley SE,et al.Development and progression of nephro pathy in type 2 diabetes:the United Kingdom Prospective Diabetes Study (UKPDS64) [J].Kidney Int,2003,63(1):225-232
85．全春兰．糖尿病肾病的预防和护理进展．解放军护理杂志2004年12月，21(12)：135
86．王娜等．糖尿病肾病的研究现状．国外医学内分泌医学分册2004，24(2)；354
87．马文，沈善康，王薇，等．江汉油田成人糖尿病患病率及其危险因素的流行病学调查．临床内科杂志2004，21(7)；476
88．曲晓璐．1718例2型糖尿病患者糖尿病肾病发病率及其中医证型分布特点．中国中西医结合肾病杂志2003，4(12)；453
89. Ansquer JC,Foucher C,Rattier S,et al.(2005).Fenofibrate reduces progression to microalbuminuria over 3 years in a Placebo-controlled study in type 2 diabetes:results from the Diabetes Atheroselerosis Intervention Study(DAIS)[J].Am J Kidney Dis 45 (3):485-93
90．金世鑫．美国糖尿病学会2007糖尿病诊疗标准(三)[J]．中国糖尿病杂志，2007，15(4)：附录
91. Baggio B,Budakovie A,Dalla Vestra M,etal.Effects of cigarette smoking on glomerular structure and function in type 2 diabetic patients[J].J Am Soe Nephrol, 2002,13(11):2730-6
92．赵日方．2型糖尿病合并早期糖尿病肾病的相关危险因素分析．长治医学院学报2007，21(4)；259
93. Lane JT.Microalbuminuria as a maker of cardiovascular and renal risk in type 2 diabetes mellitus:a temporal perspective.Am J Physiol Renal Physiol, 2004, 286; F442-F450
94. American Diabetes Association.Diabetic Nephropathy.Diabetes Care,2004,26; 94s-98s
95．王克勤．糖尿病肾病发病机制及治疗新方向．医生论坛2003，18(21)；452
96. Gall MA,Hougaard,Borch Johnsen K,et al.Risk factors for devopment of incipient and overt diabetic nephropathy in patients Withnon-insulindependent diabetes mellitus: prospective, observational incipient and overt diabetic study[J].BMJ,1997, 314;7883-7888
97. Hodgkinson AD,M ill ward BA, Demaine AG. Polymorphism of the glucose transporter (GLUT1) gene are associated with diabetic nephropathy[J].Kidney Int, 2001, 59(3): 985
98. Lee L K,Meyer T W, Pollock A S,et al.Endothekial cell injury initiates glomerular sclerosis in the rat remnant kidney.J Clon Invest, 1995,96(2):953-964
99. Sharma K,Ziyadeh F N.Hyperglycemia and diabetic kidney disease.The case for transforming growth factor-beta as a key mediator.Diabetes,1995,44,44(10):1139-1146
100. Singh R,Alavi N,Singh A K,et al.Role of angiotensin Ⅱ in glucoseinduced inhibition of mesangial matrix degradation.Diadetes, 1999,48(10):2066-2073
101. Isono M,Mogyorosi A,Han D C,et al.Stimulation of TGF-beta type Ⅱ receptor by high glucose in mouse mesangial cells and in diabetic kidney.Am J Physiol Renal Physiol,2000,278(5):F830-838
102. Wendt TM,Tanji N,Guo J,et al.RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy.Am J Pathol,2003,162(4):1123-37
103. Oh J H,Ha H,Yu M R,et al.Seqiential effects of high glucose on messangial cell transforming growth factor-beta 1 and fibronectin synthesis.Kidney Int, 1998, 54: 1872-8
104.Lupia E,Elliot SJ,Lenz O,et al.IGF-ldecrease Collagen degradation in diabetic NOD Mesangial cells:implications for diabetic nephropathy. Diabetes, 1999,48: 1638-1644
105.Browniee M.Negative consequences of glycation.Metabolism.2000;149:9-13
106.Raecah D,Coste T, Cameron NE,et al.Effect of the aldose reductase inhibitor tolrestat on nerve conduction velocity Na/K ATP ase activity,and polyols in red blood cells.scialie nerve kidney cortex,and kidney medulla of diabetic rats.J Diabetes Complications, 1998, 12:154-162
107.Okada S, Shikata K. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes[J].Diabetes, 2003, 52(10): 2586
108.Jin Y, Moriya T, Tanaka K, et al. Glumerular hyperfiltration in no-proteinuric and non-hypertensive Janpanese type 2 diabetic patients. Diabetes Rrs Clin Pract, 2005: 23
109.Remuzzi G, Perico N, Macia M,et al. The role of renin-angio-tensin-aldosterone system in the progression of chronic kidney disease[J].Kidney Int, 2005, 99(Suppl): S57-S65
110.American Diabetes Association.[J].Diabetes Care, 2004, 27(Suppl1): S79-83
111．叶山东，朱禧星．临床糖尿病学．合肥：安徽科学技术出版社，2005．194
112.Mimran A, Alfaro V.Candesartan:nephroProtective effects and treatment of. diabetic nephropathy.Drugs Today,2003:39:439-50
113.Rachmani R, Slavachevsky I, Amit M, et al.[J].Diabetic Med, 2004, 21(5): 471-475
114．向群，杨春云，姚强，等．低分子肝素钠对糖尿病肾病尿蛋白作用探讨．新医学，2004，35(3)：167
115.Moriyama T, Oka K, Ueda H, et al.[J].Clin Exp Nephrol, 2004, 8(3): 230-236
116.Inoue T, Okdaa H,Kobayashi T et al.Hepatocyte growth factor counteracts transforming growth factor-betal,through attenuation of connective tissue growth factor induction,and prevents renal fibrogenesis in 5/6 nephrectomizedmice. FASEBJ 17,2003:268-270
117.Paleologo G, Tregnaghi C, Bianchi AM, et al.[J].Transplant Proc, 2004, 36(3):591-596
118.刘新民,潘长玉,张达青,等.实用内分泌学[M].北京:人民军医出版社,2004.1471
119.Schnaper HW,Hayashida T,Hubchak SC,et al.TGF-beta signal transduction and mesangial cell fibrogenesis.Am J Physiol Renal Physiol,2003,284:F243-F252
120.Wolf G,Ziyadeh FN.Molecular mechanisms of diabetic renal hypertrophy [J].Kidney Int,1999,56(2):393-405
121.Branton MH,Kopp JB.TGF-beta and fibrosis.Microbes Infect,1999,1:1349-1365
122.Sharma K,Jin Y,Guo J,et al.Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice.Diabetes,1996,45:522-530
123.Hoshi S,Shu Y,Yoshida F,et a.Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats[J].Lab Invest,2002,82(1):25-35
124.Nakamura T,Ushiyama C,Suzuki S,et al.Urinary excretion of podocytes in patients with diabetic nephropathy[J].Neprol Dial Transplant 2000;15(9): 1379- 1383
125.Ina K,Kitamura H,Tatsukawa S,et al.Transformation of interstitial fibroblasts and tubulointerstitial fibrosis in diabetic nephropathy[J].Med Electron Microsc,2002, 35(2):8-96
126.Richard E.,Gilbert,Alison Cox,et al.Expression of transforming grow the factor-|31 and type IV collagen in the renal tubulo interstitium in experimental diabetes.Diabetes,1998,47:414
127.Poncelete AC,et al.Am J Phisiol,1998;275:458-466
128.Esaka Y,et al.J Clin Invest,1993;92:2597-2601
129.Suzuki M,Akimoto K,Hattori Y.Glucose upregulates plasminogen activator inhibitor-1 gene expression in vascular smooth muscle cells.Life Sci.2002;72(1):59-66
130.Auzuki M,A kimito K,Hattoi Y.Glucose upregulates plasminogen activator-1 gene expression in vascular smooth muscle cells.Life Sci,2002,72:59-66
131.Mcfarlane SL,Sowers JK,et al.Aldosterone function in diabetes mellitus:effects on cardiovascular and renal disesase.J Clin Endocrino.Metab,2003,85:516-523
132.Wolf G.Link between angiotensin Ⅱ and TGF-βin the kidney[J].Electrolyte Metab, 1998,25:174
133.Goldberg HJ, Scholey J,Fantus I G, et al. Glucosamine activates the plasminogen activator inhibitor-1 gene promoter through SP1 DNA binding sites glomerular mesangial cell[J].Diabetes,2000,49:863-871
134.Samad F,Yamamoto K,Loskutoff DJ,et al.Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo:induction by tumor necrosis factor-αand lipopolysaccharide[J].Clin Invest, 1996,97(1):37-46
135.Agostino G, Tonoli M,Deorsola B,et al.PAI-1 release fromhuman adipose tissue is stimulated by TNF-alpha[J].Thromb Haemost, 1997,77 [Suppl] :749
136.Liu C, Yao J, de Belle I, et al. The transcription factor EGR-1 suppress transformation of human fibrosarcoma HT1080 cells by coordinated induction of TGF-β,FN and PAI-1[J].J Biol Chem,1999,274:4400-4411
137.Wolf G, Ziyadeh FN.Kidney Int, 1999;56:393
138.Mauer SM,Steffes MW, Brown DM. Strueture functional relation in diabetic nephropathy .J Clin Invest, 1994;74:1143-1154
139．高玉洁，李冬梅．高糖对大鼠肾小球系膜细胞分泌t-PA及PAI-1的实验影响[J]．放射免疫学杂志，2004，17(2)：267
140.Ziyadeh f N,HAN D C,COHEN J A,et al.Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cells: involvement of the transforming growth factor-beta system [J].Kidney Int,1998,53(3):631-638
141.Shultz PJ,Raij L. The glomerular mesangiurn:Role in initiation and Progression of renal injury.Am J Kidney Dis 1991;17:8
142.Sinonson MS,Dunn INJ.Endothelin peptides:A possible role in glomerular imflammation,Lab Invest 1991;64:1
143.Murphy M,Godson C,Cannon S,et al. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells[J].J Biol Chem, 1999,274:5830
144.Kim SI.Han DC,Lee HB. Lovastatin inhibitstrans forming growth factor-81 expression in diabetic rat glomeruli and cultured rat mesangial cells[J].J Am Soc Nephrol,2000.11(1):80-87
145．张燕．霉酚酸酯防治早期糖尿病肾病的实验研究．2007：22
146．王箔，张军平．中药血清药理学实验方法研究概况[J]．天津中医药，2005，22(1)：86-88
147.Bao J F,Liu G Q.Study of the effect of NLZB on PC12 cell injury via serological pharmacological methods[J].J China pharm Univ(中国药科大学学报), 2000, 31 (2):126-129
148．蒙一纯，丁霞，贲长恩等，中药血清药理学应用研究展望[J]．北京中医药大学学报，1999，22(4)：42-43
149．金百胜．芦荟提取物防治糖尿病肾病的实验研究及其保护机理的初步探讨．2007：40
150.Cosio FG, et al.Effects of high glucose concentrations on human mesangial cell proliferation.J Am Soc Nephrol 1995;5(8):1600-1609
151．高俊瑞，马健飞，张全．Ⅳ型胶原与肾小球疾病[J]．临床荟萃，2001，16(12)：569-571．
152．龙若庭，何泽云．怡肾汤对5/6肾切除大鼠残肾组织形态与Co-Ⅳ及MMP-2的干预作用[J]．中国中西医结合肾病杂志，2006，7(6)：324-327
153．张月娥．纤维连接蛋白在肾小球硬化过程中的演变情况观察[J]．中华病理杂志，1987，16(1)：36-38
154.Makino T,Ono T, Muso E,et al.inhibitory effects of rosmarinic acid on the proliferation of cultured murine mesangial cells.Nephrol Dial Transplant, 2000, 15 (8):1140-1145
155．刘广建，黄荣桂，郑兴中．肾茶对糖尿病大鼠肾脏的保护作用及其机制研究[J]．中国中西医结合肾病杂志，2007，8(1)：32-34
156．任现志，汪受传，翟文生．水蛭治疗系膜增生性肾小球肾炎的探讨[]．辽宁中医杂志，2005，32(3)：244
157.Weston BS,Wahab NA,Roberts T, et al.Bacitracin inhibits fibronectin matrix assembly by mesangial cells in high glucose[J].Kidney Int,2001,60(5):1756-1764
158.Singh R, Song RH,Alavi N,et al.High glucose decreases matrix Metalloproteinase-2 activity in rat mesangial cells via transforming growth factor-beta [J].Exp Nephrol, 2001,9(4):249-257
159．张燕．霉酚酸醋防治早期糖尿病肾病的实验研究．2007：31
160.Mackay K,Stiker LJ,Stauffer JW, et al.Transforming growth factor-B:murlne glomerular receptors and responses of isolaled glomerular cells.J Clin Invest, 1989: 83(4):1160-1167
161.Li YJ,Liu ZH,Liu D,Zhu JM,Guo XH,Li LS.High glucose induced mesangial cell transforming growth factorβ1 synthesis is mediated by upregulated hexosamine biosynthesis pathway.Chinese journal of nephrology dialysis and transplantation. 2000:9(4):303-310
162.Eddy AA,Molecular basis of renal fibrosis.Pediatr Nephrol 2000;15(3-4):290-301.
163.Datta PK,Blake MC,Moses HL.Regulation of plasminogen activator inhibitor-1 expression by transforming growth factor-beta-induced physical and functional interactions between smads and Sp1.J Biol Chem2000;275(51):40014-40019
164．柳刚．糖尿病肾病大鼠肾脏细胞因子表达的变化及丹参/氮沙坦干预研究．2005：61